Clinical Trial Search

Primary: Number of Maternal Participants With Pregnancy Outcomes From Conception Until Day 42 Post-delivery of the First Pregnancy Conceived Within 2 Years Post-vaccination…

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade (RSV-seropositive Participants) — 10; 9; 4; 0 Participants

Primary: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) — 0; 0; 0; 0 Participants

Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade — 21; 22; 11; 1 Participants

Primary: Number of Participants With Solicited Adverse Events (AEs) by Grade - (RSV-seropositive Participants) — 8; 5; 0; 0 Participants

Primary: Part A: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection — 147; 395; 291 Participants

Primary: Number of Solicited and Unsolicited Adverse Events (AEs) — 17 adverse events

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) During a 7-day Follow-up Period After the First Vaccination (Administered at Day 1) — 5; 6; 0; 22…

Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants

Primary: Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After First Vaccination — 8; 1; 14; 4 Participants

Primary: Number of Subjects With Any Solicited Local Adverse Events (AEs) — 1; 2; 0; 2 Participants

Primary: RSV-A Neutralizing Titers Expressed as Adjusted Geometric Mean Titers (GMTs) at 1 Month Post RSVPreF3 OA Vaccination — 5676.7; 6329.5 Titer

Primary: Cohort 1: Number of Participants With Serious Adverse Events (SAEs) — 3; 0; 0; 2 Participants

Primary: Percentage of Participants Reporting Solicited Administration Site Events in RSV Pooled Group, RSV+Flu Pooled Group and Flu+Placebo Group — 53.6; 51.1; 34.4; 4.4…